Diptheria Pertussis Tetanus (Dpt)Vaccine Suppliers & Bulk Manufacturers
Available Forms: Injection
Available Strengths: Diph. toxoid: ≥ 30 International Units ; Tetanus toxoid: ≥ 40 International Units
Reference Brands: Daptacel®, Infanrix®(US); Boostrix® ,Tripedia® (EU)
Category:
Hepatitis
DPT vaccine injection typically contains ≥30 IU diphtheria toxoid, ≥40 IU tetanus toxoid, and either whole-cell or acellular pertussis antigens per 0.5 mL dose. This combination ensures effective protection against diphtheria, pertussis, and tetanus in infants and children.
Diptheria Pertussis Tetanus (dpt)vaccine is available in Injection
and strengths such as Diph. toxoid: ≥ 30 International Units ; Tetanus toxoid: ≥ 40 International Units.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Diptheria Pertussis Tetanus (dpt)vaccine is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Diptheria Pertussis Tetanus (dpt)vaccine can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
The Diphtheria, Pertussis, Tetanus (DPT) vaccine injection is a combined immunization product providing protection against three serious bacterial diseases. It contains standardized doses of diphtheria toxoid (≥30 IU), tetanus toxoid (≥40 IU), and whole-cell or acellular pertussis antigens per 0.5 mL dose. Administered intramuscularly, it is essential in pediatric vaccination schedules to prevent diphtheria, whooping cough, and tetanus. Manufactured under stringent EU-GMP and USFDA standards, the DPT vaccine is widely supplied for hospital tenders, public health programs, and B2B distribution in the EU and US markets, supporting immunization coverage worldwide.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing